ZDHHC22: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of ZDHHC22. The page also collects GeneMedi's different modalities and formats products for ZDHHC22 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ZDHHC22 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Predicted to enable protein-cysteine S-palmitoyltransferase activity. Involved in protein localization to plasma membrane and protein palmitoylation. Located in Golgi apparatus; endoplasmic reticulum; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]
| Target ID | GM-MP1960 |
| Target Name | ZDHHC22 |
| Gene ID | 283576,238331,299211,706468,100686021,101100646,613943,100058967 |
| Gene Symbol and Synonyms | C14orf59,Gm262,ZDHHC22 |
| Uniprot Accession | Q8N966,Q2TGI8 |
| Uniprot Entry Name | ZDH22_HUMAN,ZDH22_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000177108 |
| Target Classification | N/A |
Pre-made anti-ZDHHC22 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-ZDHHC22 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ZDHHC22 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-ZDHHC22 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Multi-species ZDH22/ ZDHHC22/ C14orf59 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ZDHHC22 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| ZDHHC22 VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |